Merl F. Hoekstra

Ngen, Inc. advanced diagnostics provides physicians and patients worldwide with sophisticated information to predict, diagnose and treat disease. Research and clinical reference labs use the highly accurate and reliable NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray and broad suite of analyte specific reagents to develop diagnostic tests for variety of diseases. Nanogen also offers a broad portfolio of patented nucleic acids chemistries and molecular tools that accelerate genomic analysis and are compatible with many systems. The SynX subsidiary offers a line of point-of-care diagnostic tests and is building expertise in cardiac related health conditions. Nanogen's ten years of pioneering research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. The company is headquartered in San Diego, CA

CEPTYR, Inc. developed pharmaceutical products. The company was founded by George Rathmann & Deborah Cool in 1995 and was headquartered in Redmond, WA.

Part of Viking Power Services, Inc., Cascade Oncogenics, Inc. makes tests for screening and diagnosis of cancer. The company is based in Portland, OR. The company was founded by Merl F. Hoekstra. Cascade Oncogenics was acquired by Viking Power Services, Inc. on April 19, 1998 for $6.80 million.

MP Bio medicals Canada Ulc provides genomics and gene delivery research tools and services. The firm’s products include PCR, transfection, protemics, lab tools and instruments, and enzyme products. It has operations in Canada, France, Switzerland and the United States. The company was founded in 1991 and is headquartered in Montréal, Canada.

Epoch Biosciences, Inc. manufactures and develops molecular tools for genetic analysis. Its technology has numerous applications including the detection of inherited diseases and single nucleotide polymorphisms to identify individuals at risk for disease or adverse drug reactions and gene expression measurement. The company was founded in 1985 and is headquartered in Bothell, WA.

Groove Biopharma Corp. focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) were involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma's core technology addressed a new avenue of nucleotide therapeutic drug discovery via modulation of cellular mirna. Used exclusive technology, Groove Biopharma were generated a series of lead candidates with the potential to be best-in-class therapeutics. By incorporated proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presented promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.The company was founded in 2008 and is headquartered in Seattle,UN.